ATE251463T1 - Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins - Google Patents

Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins

Info

Publication number
ATE251463T1
ATE251463T1 AT99919857T AT99919857T ATE251463T1 AT E251463 T1 ATE251463 T1 AT E251463T1 AT 99919857 T AT99919857 T AT 99919857T AT 99919857 T AT99919857 T AT 99919857T AT E251463 T1 ATE251463 T1 AT E251463T1
Authority
AT
Austria
Prior art keywords
compositions
prolonging
effect
clostridium neurotoxin
methods
Prior art date
Application number
AT99919857T
Other languages
English (en)
Inventor
J Oliver Dolly
Kei Roger Aoki
Paiva Anton De
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE251463T1 publication Critical patent/ATE251463T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99919857T 1998-04-29 1999-04-15 Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins ATE251463T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8347298P 1998-04-29 1998-04-29
PCT/US1999/008303 WO1999055359A1 (en) 1998-04-29 1999-04-15 Compositions and methods for extending the action of clostridial neurotoxin

Publications (1)

Publication Number Publication Date
ATE251463T1 true ATE251463T1 (de) 2003-10-15

Family

ID=22178574

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99919857T ATE251463T1 (de) 1998-04-29 1999-04-15 Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins

Country Status (10)

Country Link
US (1) US20040228881A1 (de)
EP (1) EP1073455B1 (de)
JP (2) JP2002512977A (de)
AT (1) ATE251463T1 (de)
AU (1) AU3748499A (de)
CA (1) CA2328111A1 (de)
DE (1) DE69911944T2 (de)
ES (1) ES2207208T3 (de)
HK (1) HK1032752A1 (de)
WO (1) WO1999055359A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870464A3 (de) * 1999-06-02 2008-03-12 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US20030162700A1 (en) * 2000-03-03 2003-08-28 Shipham Kylie Ann-Maree Method of treatment
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110243899A1 (en) * 2008-04-25 2011-10-06 National University Corporation Chiba University Wnt Signaling Inhibitor Comprising Insulin-Like Growth Factor-Binding Protein
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
WO2023105289A1 (en) 2021-12-06 2023-06-15 Dublin City University Methods and compositions for the treatment of pain

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5814500A (en) * 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
AU6808001A (en) * 2000-05-23 2001-12-03 Neurologix Inc Glutamic acid decarboxylase (gad) based delivery systems

Also Published As

Publication number Publication date
CA2328111A1 (en) 1999-11-04
HK1032752A1 (en) 2001-08-03
EP1073455A1 (de) 2001-02-07
ES2207208T3 (es) 2004-05-16
JP2006063085A (ja) 2006-03-09
DE69911944D1 (de) 2003-11-13
AU3748499A (en) 1999-11-16
EP1073455B1 (de) 2003-10-08
US20040228881A1 (en) 2004-11-18
DE69911944T2 (de) 2004-07-22
WO1999055359A1 (en) 1999-11-04
JP2002512977A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
ATE251463T1 (de) Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins
DE69728782D1 (de) Verwendung von no synthase hemmern und fängern von reaktiven sauerstoffsformen zur behandlung von ischämie
BR9608402A (pt) Oligonucleotìdeo anti-sentido, e, processos para inibição da expressão do raf humano, da hiperproliferação de células e para tratamento da condição proliferativa anormal.
FR2757163B1 (fr) Nouveaux derives insolubles de s-triazine, leur procede de preparation, compositions les contenant et leurs utilisations
ATE317226T1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
DE69835846D1 (de) Modifizierte hydrogenierte Polymere, Verfahren und Verwendung
DE69840987D1 (de) Physikalischer Zufallszahlengenerator, Verfahren zum Generieren von physikalischen Zufallszahlen und Speichermedium für physikalische Zufallszahlen
EA199700225A1 (ru) Способ предотвращения и лечения сенсорно-невральной тугоухости и вестибулярных нарушений с помощью белкового продукта нейротрофического фактора глиальной клеточной линии (gdnf)
DE69715325D1 (de) Apparat zum Behandlung von Bekleidungsstücken
DE69911108D1 (de) Apparat zum Behandlung von Bekleidungsstücken
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
DE69709315T2 (de) Weichmacherlotionzusammensetzung, ihre verwendung in der papierherstellung und papierprodukt
WO2002020846A3 (en) Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
ATE256740T1 (de) Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
DK1003865T3 (da) Mutation i Connexin 26 genet ansvarlig for prelingual non-syndromisk dövhed og fremgangsmåde til detektering
DE69911986D1 (de) Einrichtung und verfahren zum ausgleichen und verteilen von steueralgorithmenlasten
ATE211155T1 (de) Verzweigte polyoxyalkyl makromoleküle, verfahren zu ihrer herstellung und ihre verwendung
NO950537L (no) Polysubstituerte 3-acylamino-5-fenyl-1,4-benzodiazepin-2-on-derivater, fremgangsmåter for fremstilling derav og farmasöytiske blandinger inneholdende dem
DE60001919D1 (de) Kationische oxidationsbasen, deren verwendung als oxidative färbemittel von keratinfasern, färbemischungen und verfahren zum färben
ATE312175T1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
ATE263239T1 (de) Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
DZ2292A1 (fr) Méthode concernant l'immortalité des cellules.
TW200503717A (en) Substituted 1,4-pyrazine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties